智通财经APP获悉，礼来(LLY.US)周三宣布，其用于治疗慢性炎症性肠病的药物已获得中国监管机构批准，这意味着该疗法正式进入全球第二大药品市场。
这家美国药企在其官方微信公众号声明中表示，该药物mirikizumab(米吉珠单抗) 获批用于治疗中重度活动性克罗恩病及溃疡性结肠炎。
声明称，此次获批是礼来中国在消化免疫领域首款获批的创新药。该药物此前已在美国等多个国家获批上市。
礼来在华同时销售阿尔茨海默病、糖尿病及肥胖症等领域药物。针对该药的上市时间与定价，公司尚未立即回应置评请求。
Clarivate数据显示，在礼来这类靶向药物的上市与应用推动下，未来十年中国溃疡性结肠炎治疗市场将迎来显著增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.